215 related articles for article (PubMed ID: 12047143)
1. HER2/neu amplification in breast cancer: stratification by tumor type and grade.
Hoff ER; Tubbs RR; Myles JL; Procop GW
Am J Clin Pathol; 2002 Jun; 117(6):916-21. PubMed ID: 12047143
[TBL] [Abstract][Full Text] [Related]
2. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
3. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
[TBL] [Abstract][Full Text] [Related]
4. Her-2/neu gene amplification in ductal carcinoma in situ of the breast.
Hoque A; Sneige N; Sahin AA; Menter DG; Bacus JW; Hortobagyi GN; Lippman SM
Cancer Epidemiol Biomarkers Prev; 2002 Jun; 11(6):587-90. PubMed ID: 12050101
[TBL] [Abstract][Full Text] [Related]
5. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland.
Cornolti G; Ungari M; Morassi ML; Facchetti F; Rossi E; Lombardi D; Nicolai P
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1031-6. PubMed ID: 17938328
[TBL] [Abstract][Full Text] [Related]
6. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria.
Brunelli M; Manfrin E; Martignoni G; Miller K; Remo A; Reghellin D; Bersani S; Gobbo S; Eccher A; Chilosi M; Bonetti F
Am J Clin Pathol; 2009 May; 131(5):678-82. PubMed ID: 19369627
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the cellular centrosome in fine-needle aspirations of the breast.
Guo HQ; Gao M; Ma J; Xiao T; Zhao LL; Gao Y; Pan QJ
Breast Cancer Res; 2007; 9(4):R48. PubMed ID: 17662154
[TBL] [Abstract][Full Text] [Related]
8. HER2 genetic heterogeneity in breast carcinoma.
Ohlschlegel C; Zahel K; Kradolfer D; Hell M; Jochum W
J Clin Pathol; 2011 Dec; 64(12):1112-6. PubMed ID: 22011446
[TBL] [Abstract][Full Text] [Related]
9. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event.
Hanna W; Nofech-Mozes S; Kahn HJ
Breast J; 2007; 13(2):122-9. PubMed ID: 17319852
[TBL] [Abstract][Full Text] [Related]
11. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma?
Sullivan PS; Apple SK
Breast J; 2009; 15(2):146-54. PubMed ID: 19292800
[TBL] [Abstract][Full Text] [Related]
12. A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution.
Crowe JP; Patrick RJ; Rybicki LA; Escobar PF; Weng D; Thomas Budd G; Tubbs RR; Procop GW; Hicks DG
Breast; 2006 Dec; 15(6):728-35. PubMed ID: 16716590
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine1248-phosphorylated HER2 expression and HER2 gene amplification in female invasive ductal carcinomas.
Taniyama K; Ishida K; Toda T; Motoshita J; Kuraoka K; Saito A; Tani Y; Uike T; Teramoto S; Koseki M
Breast Cancer; 2008; 15(3):231-40. PubMed ID: 18264744
[TBL] [Abstract][Full Text] [Related]
14. [Her-2 amplification and p185 expression in invasive breast cancer cells in women].
Titi S
Ann Acad Med Stetin; 2006; 52(2):5-12. PubMed ID: 17633393
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the HER2/neu gene amplification in microdissected breast cancer tumour samples.
Seth RM; Burger AM; Kahn HJ
Anticancer Res; 2006; 26(2A):927-31. PubMed ID: 16619488
[TBL] [Abstract][Full Text] [Related]
16. Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray.
Park K; Kim J; Lim S; Han S; Lee JY
Mod Pathol; 2003 Sep; 16(9):937-43. PubMed ID: 13679458
[TBL] [Abstract][Full Text] [Related]
17. Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures.
López-Guerrero JA; Navarro S; Noguera R; Almenar S; Pellin A; Vázquez C; Llombart-Bosch A
Arkh Patol; 2003; 65(1):50-5. PubMed ID: 12669615
[TBL] [Abstract][Full Text] [Related]
18. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
Fadare O; Wang SA; Hileeto D
Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
[TBL] [Abstract][Full Text] [Related]
19. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
20. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
